Portal de Periódicos da CAPES

Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial

2024; Oxford University Press; Volume: 191; Issue: 2 Linguagem: Inglês

10.1093/bjd/ljae067

1365-2133

Sabine Altrichter, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, Martin Metz, Lila Bahadori, Maria Bergquist, Laura Brooks, Calvin N. Ho, Priya Jain, Pradeep B. Lukka, Eva Rodríguez‐Suárez, Claire Walton, Catherine Datto, Kamelia Vekovska, Jeffrey Leflein, Sonya Genova, Mariana Mandazhieva - Pepelanova, Marita Nittner Marszalska, Anna Hofman, Ana M. Giménez‐Arnau, Ricardo Tan, Hiromitsu Noguchi, Yoshiko Oda, Akihiro Kume, Seong Jun Seo, Elżbieta Szymańska, J.F. Silvestre, Jonathan A. Bernstein, Aisaku Yamamoto, Warner Carr, Grisha Mateev, Regina Treudler, Ryan Klein, Jill Waibel, Beata Imko Walczuk, Rositsa Dencheva, Young Min Park, Shunsuke Takahagi, Grażyna Pulka, Plamen Stanev, Andrea Bauer, Irida Vasileva, T. Kim, Eduardo López Bran, Martin Metz, Juan Alberto Ruano Ruiz, A. Martorell, Blakely Richardson, Kenneth Steil, Yaohan Lam, Robert Cartwright, Lon Lynn, Amal Assa’ad,

Autoimmune Bullous Skin Diseases

Chronic spontaneous urticaria (CSU) is a relatively common skin disease associated with hives and angio-oedema. Eosinophils play a role in CSU pathogenesis. Benralizumab, an anti-interleukin-5 receptor-α monoclonal antibody, has been shown to induce nearly complete depletion of eosinophils.